We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+6.86%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$4.54B
AUM Growth
+$74.3M
Cap. Flow
-$104M
Cap. Flow %
-2.3%
Top 10 Hldgs %
49.79%
Holding
155
New
7
Increased
39
Reduced
61
Closed
13

Top Buys

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$37.9M
2
AKRO
Akero Therapeutics
AKRO
+$33.4M
3
BPMC
Blueprint Medicines
BPMC
+$29.6M
4
TMO icon
Thermo Fisher Scientific
TMO
+$20.6M
5
EWTX icon
Edgewise Therapeutics
EWTX
+$19.4M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$33M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$25.4M
3
ISRG icon
Intuitive Surgical
ISRG
+$24.6M
4
BSX icon
Boston Scientific
BSX
+$18.8M
5
COR icon
Cencora
COR
+$18.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.88%
2 Technology 0.01%
3 Consumer Discretionary 0.01%
4 Communication Services 0.01%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TMDX icon
51
Transmedics
TMDX
$2.56B
$17.5M 0.39%
130,517
-43,193
-25% -$4.74M
EHC icon
52
Encompass Health
EHC
$11.1B
$16.2M 0.36%
131,741
-41,137
-24% -$4.7M
HOLX
53
DELISTED
Hologic
HOLX
$16.2M 0.36%
247,886
– –
EXAS
54
DELISTED
Exact Sciences
EXAS
$15.1M 0.33%
284,201
-294,873
-51% -$15M
MASI
55
DELISTED
Masimo
MASI
$15.1M 0.33%
89,673
+19,865
+28% +$3.17M
CDNA icon
56
CareDx
CDNA
$2.05B
$14.7M 0.32%
752,371
-136,632
-15% -$2.43M
PRVA icon
57
Privia Health
PRVA
$3.39B
$14.5M 0.32%
630,697
-66,611
-10% -$1.54M
REGN icon
58
Regeneron Pharmaceuticals
REGN
$70.9B
$14M 0.31%
26,744
-1,779
-6% -$993K
ANNX icon
59
Annexon
ANNX
$950M
$12.4M 0.27%
5,157,290
– –
HUM icon
60
Humana
HUM
$48B
$12M 0.26%
49,124
+20,826
+74% +$5.19M
MGNX icon
61
MacroGenics
MGNX
$285M
$12M 0.26%
9,919,992
-9,971
-0.1% -$14.5K
JNJ icon
62
Johnson & Johnson
JNJ
$609B
$10.4M 0.23%
68,211
+1,202
+2% +$185K
SIBN icon
63
SI-BONE Inc
SIBN
$771M
$10.2M 0.22%
540,112
-332,879
-38% -$5.52M
INSP icon
64
Inspire Medical Systems
INSP
$1.46B
$9.82M 0.22%
75,660
-23,367
-24% -$3.39M
LH icon
65
Labcorp
LH
$23.2B
$9.63M 0.21%
36,692
+8,551
+30% +$2.08M
PHR icon
66
Phreesia
PHR
$662M
$9.45M 0.21%
332,016
-44,147
-12% -$1.12M
ONC
67
BeOne Medicines Ltd
ONC
$32.4B
$9.37M 0.21%
38,698
+3,369
+10% +$826K
DGX icon
68
Quest Diagnostics
DGX
$23.3B
$8.72M 0.19%
+48,567
New +$8.44M
BMRN icon
69
BioMarin Pharmaceuticals
BMRN
$11.5B
$8.32M 0.18%
151,445
-216,928
-59% -$12.8M
INSM icon
70
Insmed
INSM
$23.5B
$8.19M 0.18%
81,397
-69,153
-46% -$5.29M
CNC icon
71
Centene
CNC
$32.8B
$7.56M 0.17%
139,310
+53,092
+62% +$3.11M
GPCR icon
72
Structure Therapeutics
GPCR
$3.45B
$7.23M 0.16%
348,527
+126,812
+57% +$2.79M
TEVA icon
73
Teva Pharmaceuticals
TEVA
$37.3B
$7.06M 0.16%
421,501
+392,571
+1,357% +$6.33M
BDTX icon
74
Black Diamond Therapeutics
BDTX
$103M
$6.78M 0.15%
2,733,547
– –
AMGN icon
75
Amgen
AMGN
$198B
$6.73M 0.15%
24,108
-56,827
-70% -$16.1M
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2025 Portfolio in Review

As of Q2 2025, Bellevue Group held 155 positions worth $4.54B, up 1.7% from $4.46B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Bellevue Group's Q2 2025 filing shows 7 new, 39 increased, 61 reduced and 13 closed positions. Its largest new stake was Blueprint Medicines: 284,900 shares worth $36.5M. The largest sale was Incyte, an estimated $33M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Bellevue Group's largest Q2 2025 buy was Blueprint Medicines: 284,900 shares worth $36.5M.
  • Bellevue Group added most to Immunocore in Q2 2025, an estimated $37.9M increase.
  • Bellevue Group's biggest Q2 2025 reduction was Incyte, cutting an estimated $33M.
  • Bellevue Group fully exited Bruker in Q2 2025, selling an estimated $14M.
  • Bellevue Group's ten largest holdings make up 50% of its $4.54B portfolio in Q2 2025.
  • Bellevue Group opened 7 new positions and closed 13 in Q2 2025.
  • Bellevue Group's portfolio value rose 1.7% quarter-over-quarter to $4.54B.

Based on Bellevue Group's 13F filing for Q2 2025, filed 14 Aug 2025.